Novartis's $90 million Swiss factory to help solve cell therapy bottleneck

Novartis's $90 million Swiss factory to help solve cell therapy bottleneck
Reuters: Health
Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020.